VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
Drug: Esketamine (Continuous infusion)
Preclinical
Small molecule
B
Beijing Tiantan Hospital
1
Indications
1
Total Trials
1
Active Trials
0
Competitors
Pipeline
Status by Indication
[3]
[1]
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Prolonged Disorders of Consciousness
Recruiting
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Prolonged Disorders of Consciousness
Preclinical
Recruiting
Clinical
Trials by Indication
[1]
Prolonged Disorders of Consciousness
1 trial
Effects of Esketamine on Consciousness-related Brain Network Characteristics in Patients With Prolonged Disorders of Consciousness
Recruiting
·
—
·
N/A
·
NCT06473285
·
80 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
1 trial record for Drug: Esketamine (Continuous infusion). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
Drug: Esketamine (Continuous infusion) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for Drug: Esketamine (Continuous infusion). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
Beijing Tiantan Hospital company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Small molecule
[2]
Highest Phase
Preclinical
[1]
Company
B
Beijing Tiantan Hospital
Related News